Physician profile
Michael J Markus
NPI 1740246297
$1,773.39
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $610 · 2020: $116 · 2021: $1,023 · 2022: $24.55.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $301.33 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $257.98 | 2019-2021 | |
| Novo Nordisk INC | $181.44 | 2020-2021 | |
| Pfizer INC. | $146.34 | 2019-2020 | |
| Lilly USA, LLC | $140.50 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.54 | 2019-2021 | |
| Amgen INC. | $77.99 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $76.87 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $65.79 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $58.62 | 2019-2021 | |
| Astellas Pharma US INC | $50.14 | 2019-2021 | |
| Glaxosmithkline, LLC. | $47.95 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $40.84 | 2019-2021 | |
| Clarus Therapeutics INC. | $39.49 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.66 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $26.30 | 2020-2021 | |
| Abbott Laboratories | $17.01 | 2021 | |
| Esperion Therapeutics, INC. | $16.72 | 2021 | |
| Eisai INC. | $16.18 | 2021 | |
| Sanofi Pasteur INC. | $14.03 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.62 | 2019 | |
| Circassia INC. | $12.58 | 2019 | |
| Allergan, INC. | $11.85 | 2020 | |
| Acerus Pharmaceuticals Corporation | $11.62 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Markus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.